Search results for: 'part testing in soil'

Since the onset of the COVID-19 pandemic, molecular diagnostics mergers/acquisition transactions and product launches for infectious disease testing are indicating a pivot toward a new direction or an enhancement of portfolios. The emergence of saliva sample testing and the transition to PCR-based syndromic and direct-to-consumer testing for respir...

01 Jul 2016  |  Europe  |  Market Research

Western Europe Point-of-Care Testing (POCT) Market

Infographics

×

Point-of-care testing is an integral part of the IVD market that is rapidly evolving into a preferred testing mode in the EU region. POCT is a segment that presents growth opportunities for a cross-section of players, ranging from OEMs to data integrators to technology vendors. The stakeholders need to be abreast of the challenges posed by the indu...

03 Oct 2022  |  Global  |  Market Research

Global Prenatal Genetic Testing—Forecast to 2026

Innovation Culture in Screening Drives Prenatal Genetic Testing Growth and Makes it Accessible to More Patients

Infographics

×

New technological advances in prenatal genetic testing include the enhancement of the next-generation sequencing (NGS) technology, chromosomal microarray analysis (CMA) tool, and PCR TaqMan. These improve precision and specificity in genome profiling, augment the efficiency and reliability of testing, and streamline workflow. The study will help...

This research service on the global pharmaceutical stability testing market addresses market sizing, emerging trends, and technologies, and provides a snapshot of the key participants in the market. The base year is 2015 and forecasts are provided from 2016 to 2020. The market is expected to grow at a CAGR of 9.4% till 2020, driven by an explosio...

As healthcare evolves toward personalized solutions, everyday consumers are proactively taking responsibility for their health in ways unimaginable a decade ago. A direct-to-consumer genetic test (DTCGT) exemplifies this trend which can be purchased and used directly by consumers without the requirement of a prescription from a healthcare provider....

In 2003, the first human genome sequence was produced, with a production cost between $500 million and $1 billion. However, since 2008, when next-generation sequencing (NGS) approaches entered the research setting, there has been a significant decline in sequencing costs. These approaches allow either the whole genome (via whole-genome sequencing [...

11 Nov 2015  |  Asia Pacific  |  Market Research

Asia-Pacific Point-of-Care Testing Market

Trends, Challenges, and Best Practices for Stakeholders

Infographics

×

Asia-Pacific (APAC) point-of-care testing (POCT) market was worth $2.80 billion in 2014. In hospitals, POC is used more in emergency rooms (ERs), operation theatres (OTs), recovery rooms (RRs), cath labs, and intensive care units (ICU). The rental model in which the cost of the device is borne by the manufacturer while the profit is shared by the h...

Reduced turnaround time and potential benefits of immediate diagnosis have resulted in an increased adoption of POCT in hospitals and physician office laboratories. However, whether POC tests replace traditional laboratory tests is a question still being debated in the scientific community. This study provides the market overview, market engineerin...

12 Aug 2021  |  North America  |  Frost Radar

Frost Radar™: Non-Invasive Prenatal Testing, Global, 2021

A Benchmarking System to Spark Companies to Action - Innovation that Fuels New Deal Flow and Growth Pipelines

Infographics

×

Non-invasive prenatal testing (NIPT) provides an alternative to invasive, higher-risk tests such as amniocentesis, requiring a maternal blood sample to obtain cell-free DNA from both mother and fetus for analysis. Since NIPTs debut in 2011, laboratories and testing companies have made incremental upgrades to their non-invasive screens, improving ac...